Learn why measuring binding affinity is key to helping you decide the next steps in your research and what technologies are available to measure it.
List view / Grid view
Learn how to measure protein stability, why it’s important, and what the key technologies are available to measure it.
Learn how fragment-based drug discovery improves hit rates and delivers higher-value targets using various biophysical methods.
Learn why researchers turned to biophysical methods to expose the molecular mechanisms of neurodegenerative diseases.
Application note: Faster and more reliable quantification of oligonucleotide interaction with human serum albumin using MST
Antisense oligonucleotides are an emerging therapeutic option for treating diseases with known genetic origin.
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
An integrated fragment-based approach, which reveals enzymatic inhibitors with potential therapeutic application, is the subject of this webinar.Taking place on 25 October 2018 at 3:00pm, the webinar is supported by NanoTemper Technologies.